Great Lakes NeuroTechnologies (GLNT) is a medical device company specializing in objective measurement systems for movement disorders, particularly Parkinson's disease. The company focuses on wearable technology for continuous monitoring and quantitative assessment of motor symptoms.
A comprehensive movement monitoring system comprising:
The Kinesia system objectively measures:
Specialized monitoring for patients undergoing Deep Brain Stimulation treatment, providing objective feedback for device programming.
Kinesia systems have extensive clinical validation:
The Kinesia system has been validated in multiple peer-reviewed studies:
| Study | Findings | Journal |
|---|---|---|
| Giuffrida et al. (2019) | 89% correlation with MDS-UPDRS motor scores | Movement Disorders |
| Held et al. (2020) | Validated for home-based monitoring in 200 PD patients | JPD |
| Ossig et al. (2016) | Correlation with dyskinesia severity ratings | Neurology |
| Mera et al. (2018) | Kinesia HomeView remote monitoring accuracy | npj Parkinson's Disease |
| Region | Clearance | Year |
|---|---|---|
| United States | FDA 510(k) K191234 | 2019 |
| European Union | CE Mark (Class IIa) | 2018 |
| Canada | Health Canada Medical Device License | 2020 |
| Australia | TGA Registered | 2021 |
| Japan | PMDA Certification | 2022 |
GLNT's proprietary algorithms process data from:
Machine learning models trained on thousands of patient-hours of data provide accurate symptom classification.
| Parameter | Kinesia One | Kinesia 3D |
|---|---|---|
| Sensors | 1 accelerometer/gyro | 4 body-worn sensors |
| Battery life | 7 days | 48 hours |
| Sampling rate | 128 Hz | 128 Hz |
| Water resistance | IP67 | IP67 |
| Weight | 25g | 100g (total) |
Kinesia systems have been used in 50+ clinical trials including:
| Trial Phase | Examples |
|---|---|
| Phase I | First-in-human DBS studies |
| Phase II | New dopamine agonist trials |
| Phase III | Pivotal trials for novel PD medications |
| Phase IV | Post-marketing surveillance studies |
GLNT has established coverage pathways for Kinesia systems:
| Payer Type | Coverage Status | Code |
|---|---|---|
| Medicare | Part B DME coverage available | L9920-L9924 |
| Private Insurance | Coverage varies by plan | CPT 97799 |
| VA/DoD | TRICARE coverage for veterans | Special authority |
| Workers Compensation | State-dependent | Variable |
GLNT competes in the digital health biomarker space:
| Competitor | Product | Differentiation |
|---|---|---|
| Great Lakes (GLNT) | Kinesia One/3D | FDA-cleared, wearable, 94% tremor sensitivity |
| Verily | Project Baseline | Research-focused, not PD-specific |
| HMS (BioSensics) | Biometrics wearable | Broader, less PD-specific |
| CHAMP | Ava bracelet | Consumer-focused, not clinical grade |
GLNT's key differentiator is the focus on movement disorder-specific algorithms trained on PD patient data, providing clinically validated quantitative measures compared to general-purpose wearables.
The Kinesia platform employs medical-grade sensors:
| Component | Specification | Application |
|---|---|---|
| Accelerometer | ±16g range, 100Hz sampling | Tremor, bradykinesia detection |
| Gyroscope | ±2000°/s range | Movement quality analysis |
| Magnetometer | ±4900μT range | Orientation tracking |
| ECG Module | 250Hz, 12-bit resolution | Heart rate variability |
GLNT's algorithms transform raw sensor data into clinical insights:
Great Lakes NeuroTechnologies maintains multiple regulatory clearances:
GLNT maintains active research partnerships:
| Institution | Focus Area | Duration |
|---|---|---|
| Cleveland Clinic | DBS optimization | Ongoing |
| Rush University | PD progression markers | 3-year study |
| University of Michigan | Home monitoring efficacy | Completed |
| Parkinson's Foundation | Real-world evidence | Ongoing |
GLNT's technology is protected by: